Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TransCode Therapeutics ( (RNAZ) ) just unveiled an announcement.
On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, designating him an independent director and financial expert with a term running until the 2026 annual meeting. Stover, who brings more than three decades of operational, financial and strategic leadership across drug development, diagnostics, specialty pharmaceuticals and SPAC-led transactions, will join TransCode’s Audit Committee and Nominating and Corporate Governance Committee, succeeding Dr. Magda Marquet on the Audit Committee; his appointment is expected to bolster the company’s governance, capital markets credibility and strategic execution as it advances its RNA and immuno-oncology programs. On December 22, 2025, the company publicly announced his appointment via press release, underscoring its emphasis on seasoned board leadership during a critical development phase for its cancer-focused pipeline.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is a Boston-based clinical-stage biopharmaceutical company pioneering immuno-oncology and RNA-based therapies for high-risk and advanced cancers, focusing on an RNA and immuno-oncology pipeline that includes candidates such as TTX-MC138.
Average Trading Volume: 146,111
Technical Sentiment Signal: Sell
Current Market Cap: $7.26M
Find detailed analytics on RNAZ stock on TipRanks’ Stock Analysis page.